GoAI
Get started
Waldencast plc logo

Waldencast plc

WALD

NASDAQConsumer DefensiveHousehold & Personal Products

Open in GoAI

Previous close

$1.30

−$0.05 · -3.70%

Aug 21, 4:00 PM ET

WALD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

43

Fair Value

Momentum

47

Neutral

Sentiment

60

Mixed

Risk resilience

39

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Waldencast Plc develops and operates a beauty and wellness platform by developing, acquiring, accelerating, and scaling the next generation of conscious, purpose-driven brands. It intends to seek brands with a direct connection to consumers whose goals include pursuing social responsibility, inclusiveness, sustainability, and transparency. The company was founded by Michel Brousset and Hind Sebti on December 8, 2020 and is headquartered in White Plains, NY.

Industry
Household & Personal Products
Sector
Consumer Defensive
Headquarters
GB
CEO
Felipe Dutra
Listed since
May 12, 2021
Employees
367

Market position

Day range

Current $1.30

52-week range

Current $1.30

Open
$1.37
Previous close
$1.35
Volume
634.84K
0.47× average
Average volume
1.34M
Average daily volume
Market cap
153.71M USD
Beta
-0.04
Market reference 1
50-day average
$1.6033
-18.92% below average
200-day average
$1.6144
-19.48% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
331.57M USD
P/E (TTM)
-0.64×
P/B (TTM)
0.33×
P/S (TTM)
0.56×
EV / EBITDA
-133.11×
Earnings yield
-107.13%
Free cash flow yield
-7.58%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
45.52%
Operating margin
-22.67%
Net margin
-84.44%
Return on equity
-49.74%
Return on assets
-28.15%
Return on invested capital
-7.84%

Financial health

Debt / equity
0.32×
Current ratio
1.7×
Altman Z-score
-0.92
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends80%20%-40%-99%Gross margin, FY2021: 61.37%Gross margin, FY2022: 23.74%Gross margin, FY2023: 64.90%Gross margin, FY2024: 48.10%Gross margin, FY2025: 45.52%Operating margin, FY2021: -1.14%Operating margin, FY2022: -44.70%Operating margin, FY2023: -37.56%Operating margin, FY2024: -21.39%Operating margin, FY2025: -22.67%Net margin, FY2021: -13.74%Net margin, FY2022: -70.20%Net margin, FY2023: -41.25%Net margin, FY2024: -15.50%Net margin, FY2025: -84.44%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 61.37%. Gross margin FY2022 23.74%. Gross margin FY2023 64.90%. Gross margin FY2024 48.10%. Gross margin FY2025 45.52%. Operating margin FY2021 -1.14%. Operating margin FY2022 -44.70%. Operating margin FY2023 -37.56%. Operating margin FY2024 -21.39%. Operating margin FY2025 -22.67%. Net margin FY2021 -13.74%. Net margin FY2022 -70.20%. Net margin FY2023 -41.25%. Net margin FY2024 -15.50%. Net margin FY2025 -84.44%.

Income trends

Revenue

272.07M USD-0.66%

Operating income

−61.68M USD-5.28%

Net income

−229.75M USD-441.31%
Income trends across reported periods324.23M USD122.78M USD−78.66M USD−280.11M USDRevenue, FY2021: 142.47M USDRevenue, FY2022: 166.13M USDRevenue, FY2023: 218.14M USDRevenue, FY2024: 273.87M USDRevenue, FY2025: 272.07M USDOperating income, FY2021: −1.63M USDOperating income, FY2022: −74.27M USDOperating income, FY2023: −81.93M USDOperating income, FY2024: −58.58M USDOperating income, FY2025: −61.68M USDNet income, FY2021: −19.58M USDNet income, FY2022: −116.62M USDNet income, FY2023: −89.98M USDNet income, FY2024: −42.44M USDNet income, FY2025: −229.75M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 142.47M USD. Revenue FY2022 166.13M USD. Revenue FY2023 218.14M USD. Revenue FY2024 273.87M USD. Revenue FY2025 272.07M USD. Operating income FY2021 −1.63M USD. Operating income FY2022 −74.27M USD. Operating income FY2023 −81.93M USD. Operating income FY2024 −58.58M USD. Operating income FY2025 −61.68M USD. Net income FY2021 −19.58M USD. Net income FY2022 −116.62M USD. Net income FY2023 −89.98M USD. Net income FY2024 −42.44M USD. Net income FY2025 −229.75M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue272.07M USD273.87M USD218.14M USD166.13M USD142.47M USD
Cost of goods sold148.24M USD82.12M USD76.56M USD126.7M USD55.04M USD
Gross profit123.83M USD131.73M USD141.58M USD39.44M USD87.44M USD
Research and development——3.2M USD4.4M USD6.09M USD
Selling, general, and administrative185.51M USD245.3M USD220.31M USD109.3M USD71.62M USD
Operating expenses185.51M USD185.28M USD223.51M USD113.71M USD89.06M USD
Interest income———12.88K USD—
Interest expense25.09M USD17.16M USD18.91M USD12.88M USD11.12M USD
Depreciation and amortization59.18M USD60.02M USD60.5M USD35.17M USD13.9M USD
Operating income−61.68M USD−58.58M USD−81.93M USD−74.27M USD−1.63M USD
Net income−229.75M USD−42.44M USD−89.98M USD−116.62M USD−19.58M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
11%
1 beat, 7 misses, 1 met estimate
Average EPS surprise
-236.05%
9 comparable reports
Latest EPS result
-0.51
Estimate -0.17 · Miss by 200.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.12-0.11-0.33-0.56Q2 '23MissQ3 '23BeatQ2 '24MissQ4 '24MetQ2 '25MissQ1 '26MissQ1 '26MissQ3 '26Estimate
Q2 2023, reported Apr 26, 2023: actual -0.03, estimate 0.005, surprise -700.00%, Miss. Q3 2023, reported Aug 10, 2023: actual 0.073, estimate 0.04, surprise +83.20%, Beat. Q2 2024, reported May 21, 2024: actual 0.01, estimate 0.04, surprise -75.00%, Miss. Q4 2024, reported Nov 20, 2024: actual -0.05, estimate -0.05, surprise 0.00%, Met estimate. Q2 2025, reported May 13, 2025: actual -0.17, estimate -0.054, surprise -214.81%, Miss. Q1 2026, reported Jan 13, 2026: actual -0.09, estimate -0.075, surprise -20.00%, Miss. Q1 2026, reported Mar 13, 2026: actual -0.51, estimate -0.17, surprise -200.00%, Miss. Q3 2026, reported Aug 24, 2026: actual —, estimate -0.17, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates149.16M115.92M82.67M49.42MQ2 '23MissQ3 '23BeatQ2 '24MissQ4 '24BeatQ2 '25BeatQ1 '26MissQ1 '26BeatQ3 '26Estimate
Q2 2023, reported Apr 26, 2023: actual 56.3M USD, estimate 65.5M USD, surprise -14.05%, Miss. Q3 2023, reported Aug 10, 2023: actual 86.99M USD, estimate 79.1M USD, surprise +9.97%, Beat. Q2 2024, reported May 21, 2024: actual 68.3M USD, estimate 69M USD, surprise -1.01%, Miss. Q4 2024, reported Nov 20, 2024: actual 63.31M USD, estimate 58.3M USD, surprise +8.60%, Beat. Q2 2025, reported May 13, 2025: actual 142.29M USD, estimate 68.08M USD, surprise +109.01%, Beat. Q1 2026, reported Jan 13, 2026: actual 66.43M USD, estimate 67.69M USD, surprise -1.86%, Miss. Q1 2026, reported Mar 13, 2026: actual 139.8M USD, estimate 66.15M USD, surprise +111.34%, Beat. Q3 2026, reported Aug 24, 2026: actual —, estimate 65.37M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$3.00

130.77% upside
Past 12 months12-month forecastHigh $3.00Average $3.00Low $3.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy250%
Hold250%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions

WALD news

globenewswire.com

Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint

LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it completed the previously announced sale of its Obagi Medical dermatological skincare and…

Read source
globenewswire.com

Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel

LONDON, June 15, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration…

Read source
globenewswire.com

Waldencast Announces Sale of Obagi Medical to Bridgepoint

LONDON, June 01, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare…

Read source

WALD peers

Walmart Inc. logo

WMT

Walmart Inc.

$103.7

-0.13%

Costco Wholesale Corporation logo

COST

Costco Wholesale Corporation

$947.74

+1.52%

PepsiCo, Inc. logo

PEP

PepsiCo, Inc.

$143.48

+0.99%

Monster Beverage Corporation logo

MNST

Monster Beverage Corporation

$47.79

+0.63%

Mondelez International, Inc. logo

MDLZ

Mondelez International, Inc.

$64.45

+0.48%

Coca-Cola Europacific Partners PLC logo

CCEP

Coca-Cola Europacific Partners PLC

$108

+1.08%

Continue in GoAI

Research WALD

research.disclaimer